Elekta

MEDTECHS DEFLATE FURTHER

13/03/25 -"It has been some time since AlphaValue last bashed MedTechs, its recurring bête noire when it comes to lofty valuations. In fairness the sector has taken care of itself of late. Five years after ..."

PDF page sample
Pages
72
Language
English
Published on
13/03/25
Download
You may also be interested by these reports :
17/03/25
DiaSorin’s Q4 results fell somewhat short of market expectations. Sales growth was primarily driven by most segments. For 2025, the company aims for ...
14/03/25
Reflecting similar reasoning from the FY23/24 actual figures, we have increased our financial expense estimates for the next two fiscal years, ...
13/03/25
Since our March 2024 idea kicker for family-controlled Elekta (Buy; Sweden) entitled ELEKTA’S CINDERELLA STORY HAS A LONG WAY TO GO, the situation ...
12/03/25
We have reduced our target price by c.11% (detail in the EPS section) but continue to foresee significant upside potential for Elekta. This optimism ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO